Abstract Dermatomyositis (DM) is an idiopathic inflammatory myopathy, which not only affects skeletal muscle and skin, but it is also associated with arthritis/ arthralgia, interstitial lung disease and cancer. The diagnostic criteria for myositis that Bohan and Peter formulated in 1975, which are often still used now, depend on the presence of a characteristic skin rash for classification of DM; without it, a diagnosis of polymyositis is given. However, advances in understanding the etiology of idiopathic inflammatory myopathies over the past few decades are impressive, encompassing discovery of myositisspecific/associated autoantibodies and development of muscle pathology, and enable us to classify them more precisely based on the underlying etiology. Correlations between clinical phenotypes and DM-specific autoantibodies (anti-Mi-2, TIF-1, NXP2, MDA5 and SAE) have been mostly elucidated, suggesting the diagnostic utility of autoantibody measurement. Advances in muscle pathology include analysis at the molecular level, such as the detection of myxovirus resistance protein A in myofibers, which can be used as a sensitive and specific pathological marker of DM. Today, a multidisciplinary approach -autoantibody profiling and pathological assessment, as well as clinical evaluation -is cardinal for a diagnosis of DM. The present review consolidates current knowledge about autoantibodies and muscle pathology in terms of diagnostic practice of DM.
Introduction
Dermatomyositis (DM) is one of the idiopathic inflammatory myopathies. Skeletal muscle and skin are mainly affected in most patients, but arthritis/ arthralgia, interstitial lung disease (ILD) and systemic manifestations, such as fever and weight loss, can also occur, and, in adult patients, cancer is more likely to be associated with the disease than other idiopathic inflammatory myopathies. [1] [2] [3] [4] [5] Heliotrope rash and Gottron's sign/papules are representative of DM skin changes. Other common skin rashes include malar or facial erythema, V-neck sign (erythema on anterior neck and chest), shawl sign (erythema on upper back and shoulder) and linear extensor erythema. Erythema on the trunk sometimes causes severely bothersome pruritus. To differentiate DM from other idiopathic inflammatory myopathies, observation of distinctive skin changes is important. However, in some patients, typical skin rashes are developed years after the onset of muscle weakness. 6, 7 Also, those skin changes are shared by antisynthetase syndrome, which has recently been considered as an independent subset of idiopathic inflammatory myopathy, implying a limitation of depending on the presence of skin changes. 2, [8] [9] [10] [11] [12] Advances in understanding the etiology of idiopathic inflammatory myopathies over the past few decades are impressive, encompassing discovery of myositis-specific/associated autoantibodies and development of muscle pathology, and enable us to classify them more precisely based on the underlying etiology. Well-defined subtyping of patients with idiopathic inflammatory myopathies will be significant, especially when designing clinical trials, because individual subsets have a specific pathomechanism. 13, 14 At present, patients with different idiopathic inflammatory myopathies are treated with roughly the same medications. However, in the era when biological (molecular targeted) therapy is becoming a realistic option, it will be reasonable to consider therapeutic strategies separately for distinct subsets. [15] [16] [17] [18] [19] In this context, the diagnostic criteria of myositis, which were formulated by , and are often still used now, do not seem appropriate for the current situation. 20, 21 In the criteria, (i) the only differential point to diagnose DM is the presence of skin involvement, and, without it, a diagnosis of polymyositis is given; (ii) the morphological criterion lacks some pathognomonic findings and analysis at the molecular level; and (iii) autoantibody evaluation is not included, from a modern standpoint. To overcome these shortcomings, some groups have tried to develop improved diagnostic criteria or classification based on autoantibody profile, muscle pathology or both, in addition to clinical phenotype. 2, 6, [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] Although international and interdisciplinary consensus has not been achieved yet, such a multidisciplinary approach is cardinal for a diagnosis of DM. The present review consolidates current knowledge about autoantibody and muscle pathology in terms of diagnostic practice of DM.
Autoantibody profile
Currently, five autoantibodies are known as DMspecific autoantibodies, which are directed toward Mi-2, transcription intermediary factor 1 (TIF-1), nuclear matrix protein 2 (NXP2), melanoma differentiation antigen 5 (MDA5) and small ubiquitin-like modifier activating enzyme (SAE), respectively ( Table 1) . Measurement of the specific autoantibodies in patients' sera will have a high diagnostic value, and furthermore it can yield information about prognosis and appropriate management.
Anti-Mi-2 autoantibody
Mi-2 (Mi-2a and Mi-2b) was reported as an autoantigen associated with myositis in 1976. 32, 33 Mi-2b is a subunit of Mi-2/nucleosome remodeling deacetylase complex, which regulates gene transcription.
Patients with anti-Mi-2 autoantibodies show typical DM skin rash. 22, [34] [35] [36] [37] The earlier studies reported that muscle weakness was usually mild, but in a recent multicenter cohort study, the patients showed severe muscle weakness at diagnosis. 38 Arthritis is sometimes seen. Several studies reported that the risk of ILD and cancer were not increased, whereas another larger cohort study suggested a possible increased risk, especially in patients with autoantibodies toward the N-terminal fragment of Mi-2b. 35 Serum creatine kinase (CK) levels are markedly elevated in most patients as compared with other subsets of DM, and could reach several thousand IU/ L or higher, being comparable with those observed in immune-mediated necrotizing myopathies (also called necrotizing autoimmune myopathies). 39 High titers of antinuclear antibodies are observed. 22, 34 The response to standard treatment (i.e. corticosteroid, in combination with immunosuppressant as required) tends to be favorable, although relapse on tapering drugs is not rare.
Anti-TIF-1 autoantibody
Anti-TIF-1 autoantibody was initially discovered as antibodies directed to 155 kDa or 155 and 140 kDa proteins independently by two different groups at almost the same time. 40, 41 Later, the 155 and 140 kDa proteins were shown to be TIF-1c (TRIM33) and TIF-1a (TRIM24), respectively, which modulate gene expression and have various functions in cellular processes including cell growth and differentiation, and carcinogenesis. 42 Some patients have anti-TIF-1b (TRIM28) autoantibodies with or without anti-TIF-1c/a. Patients with the autoantibodies have more extensive skin involvement. 43, 44 Some patients present with characteristic skin manifestations including palmar hyperkeratotic papules, psoriasis-like lesions, and hypopigmented and telangiectatic ("red on white") patches. 44 Dysphagia commonly occurs. 45, 46 Importantly 47 Subsequent studies also showed a high prevalence of cancer. 37, 42, 46, 48 In a study, cancer was found in 75% of the patients aged >40 years, and the incidence increased with age. 42 In contrast, juvenile patients do not appear to have an increased cancer risk. Cancer is mostly found within 1 year of myositis diagnosis. 46 It is unlikely that the autoantibody is linked with a specific type of cancer. This knowledge shows that comprehensive cancer screening is necessary for anti-TIF-1 adult patients. Anti-TIF-1 DM does not usually accompany ILD and prominent arthritis. A study in a large juvenile myositis registry reported that anti-TIF-1c/a autoantibodies were associated with chronic or polycyclic courses. 49 Serum CK levels can be higher than 1000 IU/L, although generally it is not so high as those of anti-Mi-2 patients. 37, 43, 46, 50 Anti-NXP2 autoantibody Anti-NXP2 autoantibody was initially called anti-MJ autoantibody, and later the autoantigen was identified as NXP2 (MORC3). 51, 52 NXP2 is associated with small ubiquitin-like modifier and required for transcriptional repression. 53 Patients with anti-NXP2 autoantibodies more commonly showed cutaneous calcinosis not only in juvenile DM, but also in adult DM, although juvenile DM patients have a high risk of calcinosis regardless of serological subsets. [54] [55] [56] [57] [58] Studies of adult anti-NXP2 patients reported a high prevalence of subcutaneous edema. 56, 57, 59 Muscle involvement tends to be severe. [55] [56] [57] 60 Dysphagia and myalgia are often described in adult patients. 56, 57 A few studies pointed out that some anti-NXP2 patients were classified as "polymyositis." 60, 61 This might be because anti-NXP2 patients generally have less intense skin manifestations, except for calcinosis, and more prominent muscle symptoms. 62 Arthritis is not common. 57, 61 The adult patients might have an increased risk of cancer. 48, 56, 57, 61 A recent study, enrolling 56 anti-NXP2 patients, found a 3.68-fold increased cancer risk (95% CI 1.2-8.6) compared with the ageand sex-matched general population, although there was no statistical difference in the prevalence of cancer between DM patients with and without anti-NPX2 autoantibodies. 56 ILD is less common than anti-NXP2-negative myositis patients. 56, 57, 61 Serum CK levels are variable, ranging from within normal range to higher than a few thousand IU/L. 54, 56, 57 Anti-MDA5 autoantibody Anti-MDA5 autoantibody was originally discovered in clinically amyopathic dermatomyositis patients as anti-clinically amyopathic dermatomyositis-140 autoantibody, which reacted with a 140 kDa cytoplasmic protein. 63 Subsequently, the autoantigen was identified as MDA5 (also known as interferoninduced helicase C domain-containing protein 1: IFIH1). 64, 65 MDA5 is a cytoplasmic RNA-specific helicase that belongs to a family of retinoic acidinducible gene I (RIG-I)-like receptors, and has a key role in antiviral innate immunity. 66 It recognizes pathogen-associated molecular patterns of viral RNA and triggers antiviral responses including type 1 interferon production. Besides classic DM skin rash, skin ulcer and palmar papules are characteristically observed. 50, [67] [68] [69] Typical areas of skin ulceration include periungual (lateral nailfold), digit pulp, part of Gottron's papule and the elbow. In Asian cohorts, proportions of anti-MDA5 patients with skin ulceration were not so high as those of the USA and UK cohorts. 50, [67] [68] [69] [70] Palmar papules are often painful, unlike Gottron's papules. Oral erosion/ulcer, alopecia, mechanic's hands and hand swelling are also often seen. Although the autoantibody is detected not only in clinically amyopathic dermatomyositis, but also in classic DM, muscle weakness is usually milder compared with other subsets. Patients are more likely to have fever and arthritis. 50, 67, 68, [70] [71] [72] [73] Importantly, anti-MDA5 patients have an increased risk of ILD. A meta-analysis of 23 studies including 618 anti-MDA5 patients showed that the odds ratio was 18.26 (95% CI 9.66-34.51). 73 Anti-MDA5 positivity is associated with poor survival secondary to rapidly progressive ILD, and the patients died within a few weeks after the onset, showing the necessity of intensive treatment without delay. 74 The association with rapidly progressive ILD has been confirmed at least in Asian populations, and also a study in a Japanese cohort has found higher antibody levels in patients with rapidly progressive ILD. 72, 75 In contrast, the association is still controversial in other populations, because there is considerable variation in results regarding the prevalence or risk among cohorts. 67, 71, 74, 76, 77 It is unlikely that anti-MDA5 autoantibody is evidently associated with cancer. 50, 67, 72 Serum CK levels are generally lower than other subsets, usually being normal or mildly elevated. 50 
Anti-SAE autoantibody
The autoantigen consists of 40 and 90 kDa proteins (SAE1 and SAE2).
78,79 SAE facilitates a post-translational modification, called sumoylation, of various proteins, leading to the formation of stable conjugates of target proteins including transcription factors. Intriguingly, sumoylation mediates transcriptional repression of Mi-2/nucleosome remodeling deacetylase complex, and also NXP2 is associated with sumoylation-mediated transcriptional repression. 53, 80 Typical DM skin rash commonly occurs a few months before muscle symptoms appear. 79, [81] [82] [83] [84] [85] A study in a Chinese cohort reported that diffuse darkred or pigment-like skin rashes were often observed. 85 Mechanic's hand and skin ulcers were also seen in some patients in the study. Anti-SAE patients often present with dysphagia and systemic symptoms, such as fever and weight loss. 79, [81] [82] [83] [84] [85] Arthritis is not common. In anti-SAE patients reported in the literature, ILD and cancer are recorded in 47% (22 of 47) and 23% (11 of 47), respectively. 85 ILD generally appears to be mild. 79, [81] [82] [83] [84] [85] [86] Serum CK levels are usually normal or mildly elevated. 81, 84, 85 Other autoantibodies Anti-aminoacyl transfer RNA synthetase autoantibodies (anti-Jo-1, PL-7, PL-12, EJ, OJ, KS, Zo and Ha antibodies) are known to cause myositis, skin rash (such as mechanic's hands; heliotrope rash and Gottron's sign are also occasionally observed 8, 12 ), arthritis/arthralgia, ILD, Raynaud phenomenon and systemic symptoms, such as fever, being called antisynthetase syndrome. Recently, several studies have shown that muscle lesions of antisynthetase syndrome have unique pathological features different from those of DM or polymyositis. The distinctive features include perifascicular necrosis (necrotic and regenerating fibers localized preferentially in the perifascicular area), upregulation of major histocompatibility complex class I and II (human leukocyte antigen-ABC and -DR) in myofibers in the perifascicular area with decreasing intensity toward central fascicular area, and myonuclear actin filament inclusions. [9] [10] [11] 87 Antisynthetase syndrome has been categorized into DM, polymyositis or occasionally overlapping myositis based on conventional classifications in clinical and research settings. 8, 20, 21, 27 However, this inconsistency is somewhat confusing. Recently, considering the particular features of antisynthetase syndrome in clinical, serological and pathological aspects, a new classification that categorizes it as an independent subset of idiopathic inflammatory myopathy has been proposed. 2 Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR) and signal recognition particle (SRP) have been regarded to be associated with immune-mediated necrotizing myopathy, which is one of the idiopathic inflammatory myopathies and characterized by subacute or chronic onset and prominent myofiber necrosis similar to muscular dystrophy. 1 It is reported that, albeit rare, patients with anti-HMGCR, especially children, and anti-SRP autoantibodies can present with a skin rash, some of whom had been given a clinical diagnosis of DM.
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General comment
The respective DM-specific autoantibodies are associated with particular clinical features. The features are similar between adult and juvenile patients with the same autoantibody, except for the incidence of cancer.
The prevalence of the autoantibodies varies among studies. 62 It was influenced partly by ethnic background and possibly more largely by difference in study design. Some studies enrolled exclusively DM patients, but others enrolled "polymyositis and DM" or "idiopathic inflammatory myopathy" patients. Furthermore, the diagnostic criteria were occasionally different. Also, some studies analyzed both adult and juvenile patients together, but others focused on either. Nevertheless, anti-TIF-1 and anti-NXP2 autoantibodies appear to form two major serological subsets of juvenile DM; the respective autoantibodies were detected in 23-35% and 22-25% of the patients, respectively, consistently in several cohorts in different regions. 41, 43, 54, 60, 62, 89 Anti-SAE autoantibody was detected almost exclusively in adult patients. 81, 85 Also, the prevalences were just 1-8%, even when restricted to adult DM patients (excluding the earliest small-sized study), suggesting that the anti-SAE autoantibody was rarer than the other DM-specific autoantibodies. 85 The potential of autoantibody measurement as a diagnostic marker is clear. Considering that autoantibody data can provide information about prognosis and appropriate management as well, we should take autoantibody measurement into account when encountering patients suspected to have DM. However, there are some practical issues regarding autoantibody tests. Immunoprecipitation is the standard method to detect the autoantibodies, but it is not suitable as a routine test. In contrast, line blot assay and enzyme-linked immunosorbent assay are handy and suitable for routine use, but the accuracy would be a concern, although most recently, improved enzyme-linked immunosorbent assays for anti-Mi-2b, TIF-1c and MDA5 antibodies have been proposed. 12, 37, 72, 90 Also, it should be noted that a considerable number of DM patients are negative for any known autoantibody.
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Muscle pathology A notable recent advance in understanding the etiology of DM is the discovery of involvement of upregulated type 1 interferon-inducible genes in muscle tissues. 92 Proteins produced from these genes' transcripts, including myxovirus resistance protein A (MxA), can be detected by immunohistochemistry on biopsied muscle samples. In addition to conventional morphological assessment, introduction of analysis at the molecular level to pathological practice will contribute to improving the sensitivity of pathological diagnosis (Table 2) .
Perifascicular atrophy
Perifascicular atrophy (PFA) means a cluster of atrophic myofibers in the perifascicular region (Fig. 1a) . PFA is associated with abnormalities at the junctional sites between the transverse tubular system and sarcoplasmic reticulum, and mitochondrial abnormalities including decreased cytochrome c oxidase activity. 93, 94 PFA has a high specificity to DM and is recognized as a pathological hallmark of the disease. 25, 26 However, there are a few shortcomings in practical use. First, the sensitivity of PFA is limited, which is mainly because a muscle biopsy sample cannot always include PFA because of its patchy distribution. In our study enrolling 34 consecutive patients with DM defined clinically or pathologically based on the criteria of the European Neuromuscular Center, just 47% of the patients showed PFA. 95 Second, small regenerating fibers in perifascicular regions, which are sometimes observed in antisynthetase syndrome, could mimic PFA (Fig. 1b) . In such case, clear judgment might be difficult, although adenosine triphosphatase stain that highlights type 2C fibers and other stains to detect regeneration can help differentiate them from atrophic degenerating fibers of PFA. Third, few anti-MDA5 patients show PFA on their biopsied muscle samples. 13 
Sarcoplasmic MxA expression
Recently, we have shown that immunohistochemistry for MxA is a more sensitive pathological marker of DM. 95 MxA is one of the type 1 interferon-inducible proteins, which normally function as defense against viral infection through a variety of means, such as inhibition of viral transcription, translation and assembly of viral nucleocapsids. 92 It is possible that chronic intracellular overproduction of MxA might be directly harmful to cells. During the past decade, Greenberg and colleagues have shown that only DM muscle samples have marked elevation of type 1 interferon-inducible transcripts, including MxA, through DNA microarray analyses. 96, 97 Their studies have also shown overexpression of MxA in cytoplasm and blood vessels in biopsied muscles of DM patients immunohistochemically. Based on the reports, we launched a study to test if MxA expression on muscle tissues served as a diagnostic marker of DM. The study showed that sarcoplasmic MxA expression was found in 71% of DM patients, and 1.7% of other idiopathic inflammatory myopathy patients including polymyositis, antisynthetase syndrome, immune-mediated necrotizing myopathy and inclusion body myositis (Fig. 1c) . 95 The sensitivity and specificity were 71% and 98%, showing that sarcoplasmic MxA expression had a higher sensitivity than that of PFA (47%), with an equally high specificity. Although the difference in the pathomechanism between adult and juvenile DM was reported, the higher sensitivity was observed in both groups (63% in adults and 90% in children).
14 In the patients who did not show PFA, but had a pathognomonic skin rash, 44% of them showed positivity of MxA. Also, sarcoplasmic MxA expression was observed in anti-MDA5 patients who lacked PFA, though there was a limited number of available samples. These results suggested that immunohistochemistry for MxA could increase sensitivity of a pathological diagnosis for DM.
Sarcoplasmic MxA expression is easy to judge on immunohistochemistry. This will contribute to minimizing interobserver variability. Also, sarcoplasmic MxA expression is hardly detected in antisynthetase syndrome, supporting the above-mentioned recent classification that categorizes it as an entity different from DM. 2 Currently, we are carrying out an international collaborative study to further validate the utility of immunohistochemistry for MxA.
Capillary membrane attack complex deposition
It has been known that membrane attack complex (MAC; also known as C5b-9) is deposited on capillaries of DM muscles, which is one of the evidence that DM should be regarded as a vasculopathic disease (Fig. 1d) . 14, [98] [99] [100] In earlier studies, 43-75% of adult DM patients and 45-100% of juvenile patients showed capillary MAC deposition. [100] [101] [102] In our recent study, the sensitivity was 35% when analyzing adult and juvenile patients together, showing that it was lower than those of PFA and sarcoplasmic MxA expression. 95 When divided into adult and juvenile patients, the sensitivity was 25% and 60%, respectively, being lower than those of PFA and sarcoplasmic MxA expression. Regarding specificity, capillary MAC deposition was seen in 15-24% of patients with immune-mediated necrotizing myopathy in our studies, although the staining pattern tended to be sparse and less intense as compared with that typically seen in DM. 39, 95 Other groups also mentioned that it was observed in polymyositis patients and other non-DM patients, although there was a difference in distribution pattern; the deposits were localized in the perifascicular area in DM, whereas they were diffusely distributed in non-DM. 102, 103 Collectively, the diagnostic value of capillary MAC deposition would not be as high as those of PFA and sarcoplasmic MxA expression. Nevertheless, Hida et al. reported that anti-TIF-1c myositis patients associated with cancer often had dense capillary MAC deposition and myofibers with nonrimmed vacuoles in their muscle samples, advocating that more rigorous examination for cancer was necessary when these findings were observed in anti-TIF-1c patients. 46 Other pathological findings RIG-I, a receptor of innate immunity that promotes type 1 interferon, is overexpressed in perifascicular areas in DM muscles. 104 A group reported that immunohistochemistry for RIG-I possessed 50% of sensitivity, which was higher than that of PFA. 105 However, patients with other forms of myositis also showed positivity of RIG-I, lowering its specificity.
Tubuloreticular inclusion (also known as lupus inclusion), which is recognized as a downstream marker of type 1 interferon signaling, is commonly visible with electron microscopy in endothelial cells of blood vessels in DM muscles. 92, [106] [107] [108] [109] In a study of adult DM, the capillary injury including the inclusion formation preceded structural changes of myofibers, suggesting it could be an early lesion in muscle tissue. 109 However, tubuloreticular inclusion can be seen in systemic lupus erythematosus, Sj€ ogren's syndrome and rarely other forms of myositis as well. 92, 110 Also, electromicroscopic analysis is not routinely carried out in a clinical setting, except at specialized institutes. Thus, its diagnostic utility might be limited practically.
Other pathological findings of DM include capillary dropout, overexpression of major histocompatibility complex class I on myofibers preferentially in the perifascicular area, myofibers with non-rimmed vacuoles (particularly observed in anti-TIF-1c DM), myofiber infarction (rarely seen in anti-MDA5 DM and possibly other subsets), ectopic lymphoid follicles and mononuclear cell infiltration. 2, 46, 95, 107, 111 The infiltrating cells consist of T cells, B cells, plasma cells and macrophages, and are distributed in the perimysium, which can cluster around blood vessels without causing angiodestructive vasculitis, and mildly in the endomysium. They do not surround or invade into non-necrotic fibers, being clearly different from the infiltration pattern in polymyositis and inclusion body myositis. These findings would not determine a diagnosis of DM, but they can support the diagnosis made by other means.
Conclusion
It is clear that autoantibody measurement serves as a useful diagnostic tool. However, there are still some practical issues, such as lack of reliable assays suitable for routine use. Also, it should be taken into account that a considerable number of myositis patients are negative for any known autoantibody. Although muscle biopsy might be optional for clinically and serologically evident patients, pathological evaluation has a significance to validate clinical and serological diagnosis, and to diagnose clinically atypical or seronegative patients. A multidisciplinary approach, including clinical evaluation, autoantibody profiling and pathological assessment, is important for a diagnosis of DM.
